[Federal Register Volume 74, Number 134 (Wednesday, July 15, 2009)]
[Notices]
[Page 34364]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E9-16697]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Antitrust Division


Notice Pursuant to the National Cooperative Research and 
Production Act of 1993--Pistoia Alliance, Inc.

    Notice is hereby given that, on May 28, 2009, pursuant to Section 
6(a) of the National Cooperative Research and Production Act of 1993, 
15 U.S.C. 4301 et seq. (``the Act''), Pistoia Alliance, Inc. has filed 
written notifications simultaneously with the Attorney General and the 
Federal Trade Commission disclosing (1) the identities of the parties 
to the venture and (2) the nature and objectives of the venture. The 
notifications were filed for the purpose of invoking the Act's 
provisions limiting the recovery of antitrust plaintiffs to actual 
damages under specified circumstances.
    Pursuant to Section 6(b) of the Act, the identities of the parties 
to the venture are: Novartis Institutes for BioMedical Research, Inc., 
Cambridge, MA; AstraZeneca UK Limited, Westminster, London, UNITED 
KINGDOM; Glaxo Group, Ltd., Brentford, Middlesex, UNITED KINGDOM; 
Pfizer, Inc., New York, NY; Accelrys Inc., San Diego, CA; ChemlTment, 
Amston, CT; ChemAxon Ltd., Budapest, HUNGARY; BioXpr, Namur, BELGIUM; 
The Edge Software Consultancy Ltd., Guildford, Surrey, UNITED KINGDOM; 
and GGA Software Services LLC, Cambridge, MA.
    The general area(s) of Pistoia Alliance, Inc.'s planned activity 
are to: (a) Streamline non-competitive elements of the pharmaceutical 
drug discovery workflow by the specification of common business terms, 
relationships and processes and to facilitate the development and 
adoption of open, accessible data standards, taxonomies, ontologies and 
Web-service descriptions (the ``Specifications''); (b) promote such 
specifications and solutions worldwide; (c) provide for testing and 
conformity assessment of implementations in order to ensure and/or 
facilitate compliance with Specifications; (d) operate a branding 
program based upon distinctive trademarks to create high customer 
awareness of, demand for, and confidence in products designed in 
compliance with Specifications; and (e) undertake such other activities 
as may from time to time be appropriate to further the purposes and 
achieve the goals set forth above.

Patricia A. Brink,
Deputy Director of Operations, Antitrust Division.
[FR Doc. E9-16697 Filed 7-14-09; 8:45 am]
BILLING CODE 4410-11-M